No Data
Minerva Launched With New Outperform at Citizens on Schizophrenia Candidate
Citizens JMP Initiates Minerva Neurosciences(NERV.US) With Buy Rating, Announces Target Price $14
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
Minerva Neurosciences: Appoints Jim O'Connor as Chief Business Officer, Effective April 21 >NERV
Minerva Neurosciences: Geoff Race, the Company's Pres, Has Elected to Leave the Co >NERV
Express News | Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia